NRSN
What one share of NeuroSense Therapeutics holds
Pharmaceutical Preparations
Enterprise, or SME, status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe
NeuroSense Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.44 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.30 |
| Cash and investments | $0.01 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$0.91 | $0.01 | −$0.67 | — | $0.51 |
| 2023 | — | −$0.74 | $0.00 | −$0.61 | — | −$0.11 |
| 2024 | — | −$0.55 | $0.00 | −$0.55 | — | $0.11 |
| 2025 | — | −$0.44 | $0.00 | −$0.30 | — | −$0.05 |